Refine
Year of publication
- 2017 (3)
Document Type
- Part of Periodical (2)
- Article (1)
Language
- English (3)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- Ants (1)
- Glomerular diseases (1)
- Mechanisms of disease (1)
- Molecular medicine (1)
- Proformica longipilosa sp. nov. (1)
- Western Palaearctic (1)
- cuticular hydrocarbons (1)
- molecular markers (1)
Institute
The taxonomy of the Palaearctic ant genus Proformica Ruzsky, 1902 is confused and in need of revision. The type specimen for P. nasuta (Nylander, 1856), the type species of the genus, was from Beaucaire, southern France, and is presumably lost. Based on extensive sampling of Proformica nests in southern France, including the type locality, we show that the concept of P. nasuta has been erroneous for more than a century. We integrate information from the morphology of workers and sexual castes, DNA markers, and cuticular hydrocarbons to re-define species in southern France. This allowed us to provide a new, accurate description of P. nasuta and designate a neotype, as well as reference individuals for all castes. In addition, we propose a name, P. longipilosa sp. nov., for a species that since the end of the 19th century has mistakenly been included in P. nasuta.
Crescentic rapidly progressive glomerulonephritis (RPGN) represents the most aggressive form of acquired glomerular disease. While most therapeutic approaches involve potentially toxic immunosuppressive strategies, the pathophysiology remains incompletely understood. Podocytes are glomerular epithelial cells that are normally growth-arrested because of the expression of cyclin-dependent kinase (CDK) inhibitors. An exception is in RPGN where podocytes undergo a deregulation of their differentiated phenotype and proliferate. Here we demonstrate that microRNA-92a (miR-92a) is enriched in podocytes of patients and mice with RPGN. The CDK inhibitor p57Kip2 is a major target of miR-92a that constitutively safeguards podocyte cell cycle quiescence. Podocyte-specific deletion of miR-92a in mice de-repressed the expression of p57Kip2 and prevented glomerular injury in RPGN. Administration of an anti-miR-92a after disease initiation prevented albuminuria and kidney failure, indicating miR-92a inhibition as a potential therapeutic strategy for RPGN. We demonstrate that miRNA induction in epithelial cells can break glomerular tolerance to immune injury.